Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

ALG Health Receives NIOSH Approval


“N95 is the standard within the medical industry, and achieving that level of quality, verifies that we are doing things the right way”

ALG Health announced today that they have received NIOSH approval for their first line of “Made In the USA” respirator masks. NIOSH approval allows the company to officially designate the product as N95, meeting the Occupational Safety and Health Organization and Center for Disease Control (CDC) product and manufacturing standards.

“We’re excited for what this means for our customers and our manufacturing team,” said Adam Harmon, President and CEO of ALG Health. “N95 is the standard within the medical industry, and achieving that level of quality, verifies that we are doing things the right way,” Harmon continued.

During the pandemic, the lack of personal protective equipment (PPE) manufactured in America has become a top-level issue among many organizations. Claims of price gauging, rampant quality defects, and delivery failures have hampered the medical community’s ability to secure these products as needed. Producing more PPE products in the United States will ensure that as we continue to fight the virus, these life-saving products will be available when and where they are needed.

To ensure that the product and manufacturing process meet the given requirements, NIOSH approval requires both a documentation and facility review. Not only must the product filter particulates at or above 95%, but the manufacturing and quality assurance procedures must also qualify. “The entire NIOSH organization has been great to work with during this time,” Harmon noted, “even during this pandemic, they prioritized getting American manufacturers through the process as efficiently as possible.” ALG Health has several more product lines submitted for approval and continues to work through the process on each of those.

The company has recently expanded its manufacturing capabilities to include a 100,000 sq ft facility in Bryan, OH but does not plan to stop there. “Our number 1 priority is to get the Bryan facility staffed and fully operational,” Harmon said, “we know that to meet the increasing demand, we can not stop there. We are actively looking at other locations around the country to increase our manufacturing capabilities.”

About NIOSH

The Occupational Safety and Health Act of 1970 external icon established NIOSH as a research agency focused on the study of worker safety and health, and empowering employers and workers to create safe and healthy workplaces. NIOSH is part of the U.S. Centers for Disease Control and Prevention, in the U.S. Department of Health and Human Services. It has the mandate to assure “every man and woman in the Nation safe and healthful working conditions and to preserve our human resources.” NIOSH has more than 1,300 employees from a diverse set of fields including epidemiology, medicine, nursing, industrial hygiene, safety, psychology, chemistry, statistics, economics, and many branches of engineering.

About ALG Health: ALG Health is a 2020 division of the parent company, Axis LED Group, a manufacturer of commercial and governmental LED lighting. Using its manufacturing expertise, ALG Health produces personal protective equipment, including disposable surgical masks and medical-grade respirators. Having received NIOSH approval, the company concentrates on servicing the medical community, first responders, military, and humanitarian efforts. For more information, check out http://www.alg-health.com.

Todd R Yunker

ALG Health

Direct (910) 282-8987

todd@alg-health.com

Share article on social media or email:

Sharon Hochhauser, FNP-C with Advanced Dermatology PC Offers Tips to Patients Going ‘Under the Light’ to remove unwanted hair


Sharon Hochhauser, Board-Certified Family Nurse Practitioner

Indeed, the thickness of skin, skin pigmentation, and hair color are all factors affecting the efficacy of laser hair removal.

When it comes to removing unwanted hair, let there be light.

So, says certified family nurse practitioner Sharon Hochhauser, who emphasizes that advancements in laser light technologies and technique, along with ongoing studies of hair biology, have made hair removal from almost any part of the body effective – and long-term. “We have come a long way since the mid-1990s when laser light was first applied successfully to skin in order to damage hair follicles as a way of preventing hair regrowth,” says Hochhauser of Advanced Dermatology, PC and the Center for Laser & Cosmetic Surgery. “Today, patients can undergo laser therapy with maximum benefits and few side effects.”

Researchers agree. However, in a study published online in April 2020 in the journal Dermatology Practical & Conceptual, authors suggest that photoepilation – therapeutic light therapy — remains most effective in patients with “relatively fair skin” and dark hair. “The major challenge,” the scientists write, is “development of technology that not only permanently and significantly reduces the number of hairs but also provides permanent and complete hair removal for all skin and hair types and colors.”

“Indeed, the thickness of skin, skin pigmentation, and hair color are all factors affecting the efficacy of laser hair removal,” Hochhauser explains. “Photoepilation is most successful when a strong color contrast exists between skin and hair pigments. The melanin in the hair follicle is what is supposed to absorb laser light, leaving the remaining skin cells unaffected. Melanin is the biochemical that gives color to hair and skin.”

Laser therapy oftentimes proves less effective in patients with minimal differences between hair color and skin tone. Outcomes also can be impacted by hair follicles not able to soak up light readily, namely those that are white, blond, red or grey in color. The good news is that “continuing development of new laser devices is rapidly providing more treatment options for patients with darker skin tone and those who have more lightly colored follicles,” Hochhauser says.

Laser and intense pulsed light (IPL) therapies work by directing specific wavelengths and duration of light to an area of the body targeted for hair removal. When the melanin in the hair follicles soaks up the light, the basal cells within the follicles heat up and die. Scientists say the “clearance rate” of follicles subjected to laser light is 20 percent to 75 percent, which is why as many as six or more laser sessions may sometimes be necessary to remove nearly all unwanted hair growth from an area.

Though their end goal is primarily cosmetic, light therapies designed to remove undesired hair from highly visible areas like armpits, legs, arms, upper lip, back – even the bikini line — are considered medical procedures that can pose risks, such as skin irritation, skin pigment changes, and, on rarer occasions, blisters, burns and infections. That is why they should be performed by trained health care professionals, Hochhauser states.

Of course, the ultimate intent of hair removal is to enhance a patient’s quality of life — a key reason why the number of laser hair procedures has been climbing – well ahead of less effective – and slower — methods like waxing, tweezing and even electrolysis (heating of skin using an electric current), Hochhauser adds.

A 2018 report predicts overall market rate of growth for hair removal products and procedures will average about 16 percent annually through 2026. The increased safety of devices, including the highly precise diode laser, and greater demand for less-invasive treatments are fueling the increase, the report states.

One specific area of growth is in home IPL therapy devices, which are becoming increasingly less expensive. However, Hochhauser warns that such devices lack strict safety review by the federal Food and Drug Administration, are not supported by any long-term studies demonstrating their effectiveness in comparison with laser therapy performed by health professionals and may fail to meet consumers’ expectations for complete hair removal.

For patients who are considering laser or other therapeutic light therapy to remove unwanted hair, Hochhauser offers these tips:

  •     Consult first with a dermatologist who has extensive clinical experience in hair removal. Not every patient is an appropriate candidate for laser therapy. Patients taking medications that increase skin photosensitivity could be burned in the procedure. Laser therapy also is less effective in patients with hormonal imbalances or hormonal changes due to pregnancy or disease.
  •     Expect the area of the skin treated by laser to feel irritated – akin to a sunburn – for a few days following the procedure.
  •     Avoid the sun for five days to seven days after a laser session and wear sunscreen on the treated skin for at least a month after therapy.
  •     Know that the removal of hair is not “100 percent forever.” Some hair follicles will survive and again produce hair, although the new hair may be lighter in color and less visible to others.
  •     “Finally, if you insist on performing the procedure at home with a store-bought device, please read the instructions closely and follow all safety precautions,” Hochhauser advises.

Sharon Hochhauser is a board-certified family nurse practitioner specializing in dermatology with Advanced Dermatology PC.

Advanced Dermatology P.C. and the Center for Laser and Cosmetic Surgery (New York & New Jersey) is one of the leading dermatology centers in the nation, offering highly experienced physicians in the fields of cosmetic and laser dermatology as well as plastic surgery and state-of-the-art medical technologies. http://www.advanceddermatologypc.com

Share article on social media or email:

The World’s Largest Egg Donor Database


News Image

TULIP, the world’s largest consumer-directed egg donor database launched today, encompassing 90 percent of all U.S. donors. The simple, do-it-yourself online search platform is now helping intended parents navigate the challenging process of finding an egg donor – empowering them with vast egg donor choice, expert knowledge and coaching support.

“Infertility affects 14 Million women and men in the U.S., who collectively spend $17 Billion annually on fertility services,” said Gail Sexton-Anderson, Chair and Co-Founder of TULIP. “The third-party fertility market itself is a loose collaboration of hundreds of agencies and clinics that operate independently, making it a daunting and challenging process for intended parents. We designed TULIP to consolidate the market and provide transparency to hopeful parents at a time when consumers demand access and dependable information.”

Founded by the team that built Donor Concierge, the leading third-party fertility service, TULIP provides access to an array of donors, surrogates and services through their immense network of fully-vetted agencies throughout the U.S.. Hopeful parents can quickly find unbiased intel, gain access to medical clinics, expert legal advice as well as psychological and genetic resources. In addition, TULIP’s team of experts are trusted by doctors and fertility professionals around the world, with over 60 percent of the brand’s users being referred by fertility professionals.

“Our goal is to match our clients with the best available candidates who are a good fit for their family,” continued Sexton-Anderson. “Our proprietary software makes searches faster and more comprehensive, while our team provides the one-on-one support that humanizes the process for hopeful parents.”

For more information, visit http://www.tulipfertility.com.

Share article on social media or email:

CISCRP Educational Webinar on How Clinical Research Affects You Aired November 18


The online program offered organizations the opportunity to share educational health and clinical research information directly to diverse patient communities and the general public.

Progress in medical science would be delayed were it not for the people volunteering their time and energy to be part of clinical trials. The AWARE for All – Los Angeles webinar aimed to raise awareness of the importance of clinical research and participation.

The Center for Information and Study on Clinical Research Participation (CISCRP) invited the Los Angeles community to attend AWARE for All – Los Angeles, a free educational webinar on Wednesday, November 18th, 4-6pm PDT via a customized, secure online platform. Viewers learned about the clinical research process, how clinical trials work, and what to expect as a study participant. The webinar included a lively, facilitated conversation with patients, researchers and healthcare professionals after an overview presentation given by Dr. Jonathan Jackson, Ph.D., Director of Community Access, Recruitment, and Engagement (CARE) Research Center, Massachusetts General Hospital and the Harvard Medical School. Two health exercises were part of the online program—Memory/Brian Health offered by Alzheimer’s Los Angeles and Reiki offered by WESpark Cancer Support Center.

Dr Leanne Burnham of City of Hope shared her thoughts on certain factors that contribute to a positive study experience, such as trust in the institution, the team and when there is that patient-physician match and language matched materials that can help study participants feel more comfortable.

Tomma Hargraves is a clinical trial participant and credits her participation with surviving Stage 3 lung cancer 14 years ago. Since then, she has participated in other clinical trials and serves as a patient liaison helping others navigate clinical trials.

CISCRP’s AWARE for All – Los Angeles program is supported by local research teams, advocacy groups, and a consortium of pharmaceutical, biotechnology and service provider organizations. The online program offered organizations the opportunity to share educational health and clinical research information directly to diverse patient communities and the general public.

A virtual health fair with local and national health and wellness organizations providing educational resources was also part of the platform, including a movie theatre experience with brief videos about clinical research.

For many clinical research participants, the decision to join a study is empowering and a way to take more control of their healthcare. The AWARE for All program emphasized the stringent ethical criteria that regulate clinical trials and protect patients who are enrolled as well as the opportunities clinical research provides to scale health equities globally.

AWARE for All – Los Angeles Clinical Research Webinar was held Wednesday, November 18th, from 4-6pm PDT. Attendance was free, but pre-registration was required. To learn more, visit awareforall.org or call 877-633-4376.

The AWARE for All – Los Angeles supporters include Allergy & Asthma Network, City of Hope, Pancreatic Cancer Action Network, PALS for Health, Alzheimer’s LA, Debbie’s Dream Foundation, Alliance for a Better Community, Being Alive LA, WeSPARK Cancer Support Center, Providence Clinical Research, Peer Plus, and the AWARE Industry Consortium.

About CISCRP

The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit http://www.CISCRP.org for more information or to participate in CISCRP’s educational initiatives. For additional questions about AWARE for All, contact awareforall@ciscrp.org or call 877-633-4376.

Share article on social media or email:

Cisive Recently Named a CEO Today USA Awards 2020 Winner


Cisive Recently Named a CEO Today USA Awards 2020 Winner

This distinction serves as a testament to our innovative approach during a year that has shaken the world and every industry. More than ever, however, we remain focused on our mission in delivering the highest quality background screening service to the industries we serve.

Cisive, a global provider of compliance-driven human capital management and risk management solutions, has been recognized by CEO Today magazine’s USA Awards. President and CEO of Cisive, James Owens, was announced as a winner of the CEO Today USA Award 2020. Every year, CEO Today magazine identifies and honors the most outstanding and forward-thinking leaders in business.

CEO Today’s research team draws on the views of thousands of stakeholders including investors, analysts, employees, and media professionals worldwide to compile its annual USA Awards. The CEO Today USA Awards celebrate the success, innovation and strategic vision of CEOs within the country, across a number of sectors and industries.

“Cisive is honored to be recognized as a winner of the CEO Today USA Award,” said James Owens, President and CEO at Cisive. “This distinction serves as a testament to our innovative approach during a year that has shaken the world and every industry. More than ever, however, we remain focused on our mission in delivering the highest quality background screening service to the industries we serve.”

Cisive’s core onboarding and pre-employment background screening offering provides clients with a streamlined, high quality, and regulatory compliant solution. The company’s comprehensive services include background screening, vendor/contractor screening, executive screening, drug testing, fingerprinting, paperless onboarding, electronic Form I-9/E-Verify, and a suite of COVID-19 compliance solutions to help employers maintain a safe workplace.

In addition to being named a winner of the CEO Today USA Award, Cisive has recently been honored by HRO Today in their 2020 Backer’s Dozen rankings of top Pre-Employment Screening Providers as well as being named as one of CIO Bulletin magazine’s 5 Best HR Tech Solution Providers of 2020. For more information about Cisive’s suite of solutions, visit http://www.Cisive.com.

About Cisive

Cisive is a global leader in compliance-driven human capital and risk management solutions, providing onboarding and pre-employment background screening solutions to address the complex challenges and needs of large enterprises with dedicated, in-country account management teams committed to customer satisfaction. Cisive is accredited by the Professional Background Screeners Association (PBSA) and was named for the fourth consecutive year by HRO Today to the 2020 Baker’s Dozen Customer Satisfaction rankings of Top Pre-Employment Screening Providers, in addition to being named Company of the Year by CIO Review. The company and its brands serve clients in financial services, transportation, telecom/media, healthcare, utilities and the home services end-markets, among others. For additional information, please visit http://www.cisive.com.

Share article on social media or email:

Vermont Organic Science Releases a New USDA Certified Organic CBD Balm


Vermont Organic Science – a Williston-based family-run organic hemp extraction lab known for its high-quality products – is excited to announce the release of a new USDA certified organic CBD balm.

With over 4% CBD as well as the cannabinoids CBG and CBC, the cbdVOS Full Spectrum Extra Strength 1100mg CBD Balm is highly potent and one of the strongest CBD topical products currently on the market. This full spectrum CBD topical is USDA certified organic and only contains certified organic ingredients. It also contains organic menthol and the essential oils of sweet almond, tangerine, frankincense, and lavender – all designed to provide deep relief to consumers.

While supplies last, enjoy a free 500mg CBD oil bottle with every purchase of the balm.

Share article on social media or email:

University of Maryland, Carnegie Mellon, and Facebook Team Up to Forecast Coronavirus Spread


“Better data can help governments determine where to send resources such as ventilators and personal protective equipment.” – Mark Zuckerberg

Social data researchers at the University of Maryland Social Data Science Center (SoDA) and Carnegie Mellon University Delphi Research Group have forged a unique partnership with social media giant Facebook to predict the spread and future hotspots of COVID-19 as well as identify patterns in preventative measures – allowing for earlier detection of outbreaks and helping public authorities to respond to the pandemic.

In an op-ed from Facebook’s founder and CEO Mark Zuckerberg, released earlier this year, Zuckerberg addresses the global challenges societies face before they can safely reopen and “how better data can help governments determine where to send resources such as ventilators and personal protective equipment.” As the most widely used social media platform in the world, Facebook is uniquely positioned to help gather this data.

Under the leadership of SoDa and the Delphi Group, the voluntary and anonymous International COVID-19 Symptom Survey was launched earlier this year. Facebook shares a link to a survey* conducted by CMU and UMD, which asks individuals about their COVID-19 behaviors and resources, such as testing availability, mask usage, and symptoms. To-date, 30+ million Facebook users from over 200 countries have participated in the survey.

Through global and national (US) geographic data visualization tools (https://dataforgood.facebook.com/covid-survey, https://covidcast.cmu.edu/) , the aggregate information can be seen alongside data such as the number of cases, number of deaths, and frequency of COVID-19 google searches by residents, providing a more holistic view of the COVID-19 pandemic.

The SoDA and Delphi teams are currently focusing their efforts in understanding mask usage trends and correlations to COVID-19 case rates. Face masks have been identified as one of the most crucial measures to slow transmission and have been a cornerstone of recommendations and policy, yet data available on usage has previously been minimal. Global (SoDA) and domestic (Delphi) early findings have been posted indicating a positive correlation between mask use and reduced spread.

The insights produced through this partnership will aid researchers, health organizations, and governments in responding to the COVID-19 outbreak, slowing the spread, and beginning to plan for recovery. The aggregate survey data from UMD and CMU is publicly available and the individual-level non-aggregate data is available to researchers and nonprofits upon request (https://dataforgood.fb.com/docs/covid-19-symptom-survey-request-for-data-access/).

*Facebook does not have access to the raw data shared by survey respondents

For more information or to schedule an interview, please contact:

  • US Data & Implications: Dr. Alex Reinhart, Carnegie Mellon University, areinhar@stat.cmu.edu
  • Global Data & Implications: Dr. Frauke Kreuter, University of Maryland, fkreuter@umd.edu

Share article on social media or email:

eMDs and Homecare Homebase (HCHB) Partner to Offer Integrated EHR Solutions for Home Care/Hospice Facilities and Care Providers


“We are delighted to partner with the market leader in home and hospice care technology. eMDs’ integration with HCHB will support critical and timely patient information flow needed between physician practices, palliative providers and homecare clinicians.”

Today, Homecare Homebase℠ HCHB) and eMDs announced an exciting new partnership that will further enhance HCHB’s mission to increase efficiency and empower exceptional patient care. As part of the partnership, HCHB will offer the eMDs Aprima 2015 Certified EHR solution to providers working with patients in hospice and palliative care settings.

“As the leading software for home health and hospice care, we are delighted to be partnering with eMDs, a physician technology company with an equally fantastic reputation”, stated Scott Pattillo, HCHB Chief Strategy Officer. “The eMDs Aprima solution is a perfect complement to the HCHB platform, particularly for those home care and hospice care organizations who need a 2015 Certified EHR in order to participate in the CMS Primary Care First program, serving the Seriously Ill Population (SIP). We’re pleased to announce this relationship, through which we are further empowering our customers to provide exceptional care.”

“This is a win-win for palliative, hospice, and home care providers, and not just those that are participating in the SIP program”, stated Derek Pickell, eMDs’ CEO. “We are delighted to partner with the market leader in home and hospice care technology. eMDs’ integration with HCHB will support critical and timely patient information flow needed between physician practices, palliative providers and homecare clinicians.”

Uniquely, both eMDs and HCHB offer true mobile and offline technologies so that patient records are always available regardless of connectivity in a particular care setting. eMDs Aprima’s ground-breaking “ClickLESS” workflows dramatically save time during encounters, helping physicians focus on their patients. Aprima is also exceptional at managing the critical patient referrals workflow needed for home care.

About Homecare Homebase, LLC

Homecare Homebase (HCHB) is a Dallas-based software leader offering hosted, cloud-based solutions to streamline operations, simplify compliance and boost clinical and financial outcomes for homecare and hospice agencies. Our customized mobile solutions enable real-time, wireless data exchange and communication between field clinicians, physicians and office staff for better care, more accurate reporting and faster payment. Founded by industry veterans in 1999, the company is now part of the Hearst Health network. For more information visit http://www.hchb.com or call us toll-free at 1-866-535-HCHB (4242).

About eMDs, Inc.

eMDs combines leading technologies with tailored services to remove operational burden and empower healthcare providers to maximize the impact of their care. Founded by physicians, eMDs brings decades of expertise and understanding to our integrated electronic health records products, practice management software, revenue cycle management solutions and credentialing services for medical practices and enterprises. With tens of thousands of deployed clients across a range of specialties and settings, eMDs’ extensive experience allows us to craft proven, transformative, solutions that meet the unique needs of healthcare organizations, enabling unmatched productivity and a superior experience for patients and practitioners alike. Expert Solutions. Stronger Partners. Healthier Patients. Connect with us at http://www.emds.com.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 103 million home health visits and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email:

OptionRx, Launched by TroyRx, will Transform the Prescription Experience for Patients at the Point of Care


“We are advancing prescription adherence by making it simple for patients to access all the available affordability options for any medication, at the time it is prescribed, so they can make the best choice.”

TroyRx, an industry leader in prescription software solutions, announces the launch of OptionRx, a cloud-based platform that activates patient engagement at the time of prescribing.

OptionRx  is the first patient engagement platform that delivers drug education, cost transparency and affordability options for all prescriptions directly to the patient. This new solution expands TroyRx’s innovative Rx software capabilities and advances the company’s mission to improve the prescription experience for providers and patients.

As a patient-centric solution delivering true price transparency, OptionRx informs discharged patients of the most affordable option for their prescriptions. The whole system is powered through connections with Pharmacy Benefit Managers, pharmacies, medication databases, and drug manufacturers. That is how OptionRx can share the widest breadth of savings offers and cost transparency.

Copay assistance programs, cash discount pricing, and benefits information is available in a patient-friendly mobile view. Patients can now leave their visit with resources that educate them about their medication and empower them to make the best choice to overcome cost barriers with and without insurance.

“Cost-based medication abandonment is a growing concern of the healthcare providers we serve. They are recognizing how affording prescriptions is top of mind for their patients,” said Craig Baldassare, General Manager of TroyRx. “There is significant investment across healthcare for driving price transparency and offering drug affordability and discount options, but they go underutilized because patients are not informed about them. We are advancing prescription adherence by making it simple for patients to access all the available affordability options for any medication, at the time it is prescribed, so they can make the best choice.”

Purpose-built for providers and hospitals, OptionRx seamlessly integrates into EMRs, where the medication ordering process triggers machine learning-based, cloud services. Personalized, prescription-specific resources are dynamically matched to orders and delivered to the patient. OptionRx enhances prescriber-patient communication without adding any steps to the provider’s current prescription workflow.

With the launch of the OptionRx patient engagement platform, TroyRx continues to innovate solutions that revolutionize the prescription experience for providers, patients, and health systems. To request a demo or learn more about TroyRx’s integrated prescription solutions, please email advantages@troyrx.com or visit https://www.troyrx.com/.

About TroyRx

Providers and patients inspire the TroyRx team to create prescription solutions purpose-built to drive digital transformation, compliance, and medication adherence. It’s been that way since 2008 when we released healthcare’s first CMS compliant, plain paper prescription printing product. We serve the nation’s largest health systems and provider networks and count leading EHRs as strategic partners.

Share article on social media or email:

Strategies to Optimize Your Drug-Drug Interaction Program, Upcoming Webinar Hosted by Xtalks


Join this educational webinar to hear three specialists share their expertise on how sponsors can optimize their DDI evaluation process, spanning from preclinical to clinical.

What sponsors always wanted to know about DDI waivers, cocktails and modeling, but were afraid to ask.

As today’s patients are prescribed an increasing number of medications, drug development sponsors must be aware of potential drug-drug interactions (DDIs) for their product in order to avoid unexpected pharmacological effects and to provide accurate labeling.

Join this educational webinar to hear three specialists share their expertise on how sponsors can optimize their DDI evaluation process, spanning from preclinical to clinical.

The first part of this webinar will provide an overview of in vitro DDI assays and the use of physiologically-based pharmacokinetic (PBPK) modeling to help interpret results, support waivers and focus on interactions with clinical DDI risk, before moving into study design considerations to ensure robust and efficient assessment. Population pharmacokinetics (PopPK) strategies will then be presented to explain how modeling and simulation can help evaluate DDI risk and support labeling.

Join experts from Covance, Dan Albaugh, MS, Associate Director, Global Metabolism and Environmental Sciences; Andreas M. Reichl, MD, Scientific Director, Clinical Pharmacology, Medical and Scientific Affairs; and Brandon Gufford, PharmD, PhD, Senior Pharmacokineticist, Clinical Pharmacology Services, in a live webinar on Monday, December 7, 2020 at 10am EST (3pm GMT/UK).

For more information, or to register for this event, visit Strategies to Optimize Your Drug-Drug Interaction Program.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: